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There is a need to develop a test to detect GH abuse by elite
athletes. Measured levels of GH in blood or urine, however,
provide little informationon theGH-IGF-I axis.Previous stud-
ies have identified a series of indirect markers of GH action
that are markedly altered by the administration of GH, but to
a lesser degree by acute exercise. This study was undertaken
to determine the physiological range of these GH-dependent
variables in elite athletes after a competitive event to deter-
minewhether suchvaluesdiffer fromrestingvalues innormal
and athletic subjects and to establish whether any adjust-
ments to this range are required on the basis of age, gender,
demographic characteristics, or the nature of the exercise
performed. Serum samples were collected from 813 elite ath-
letes (537 males and 276 females; age range, 17–64 yr) from
15 sporting disciplines within 2 h of completion of a major
competitive event. IGF-I, IGF-binding protein 2 (IGFBP-2),
IGFBP-3, acid-labile subunit, and the bone and soft tissue
markers, osteocalcin, carboxyl-terminal propeptide of type I
procollagen, carboxyl-terminal cross-linked telopeptide of
type I collagen, and procollagen type III were measured.
Sporting category, gender, age, height, weight, body mass in-
dex (BMI), and racial group of the athlete were documented,
and results were compared both to normative data and to
values obtained from elite athletes under resting conditions.
Forty-one percent of IGF-I values in male athletes and 41% of
values in female athletes were above the upper limits of 99%
reference ranges derived from resting values in a normal pop-
ulation. Postcompetition levels of all variables except carbox-
yl-terminal propeptide of type I procollagen and carboxyl-
terminal cross-linked telopeptide of type I collagen differed
fromrestingvalues. Therewasaconsistent age-dependent fall
in measured levels of all variables (P < 0.0001) with the ex-
ception of IGFBP-2, which increased with age (P < 0.0001).
BMI, but not height, exerted a small, but significant, influence
on several variables. After adjustment for age, there were no
significant differences in the levels of any of the measured
variables between sporting categories. IGFBP-2 and IGFBP-3
were lower in 35 black athletes compared with those in 35
white athletes matched for age, gender, height, BMI, and
sporting category. We have demonstrated that there are pre-
dictable age-dependent levels of GH-dependent markers in
elite athletes that are consistent even at the extremes of phys-
ical exertion and that these are independent of sporting
category.Normative data applicable towhite athletes are pro-
vided. This provides important groundwork for the develop-
ment of a test for GH abuse, although these values may be
specific for the reagents and assays used. (J Clin Endocrinol
Metab 90: 641–649, 2005)
THERE IS AN increasing body of evidence that GH is widelyabused by athletes and sportsmen as a performance-
enhancingagent.Althoughthereisnorobustepidemiologicaldata
concerning the extent of GH abuse, anecdotal evidence as well as
theseizureofGHsuppliesbypoliceandcustomsofficials suggests
that it represents a significant problem in a number of sports,
including track and field, swimming, and cycling (1, 2).
GH is a powerful metabolic hormone; its absence in GH
deficiency leads to decreased lean bodymass, increased body
fat, decreased exercise capacity, and increased fatigue (3–5).
GH replacement in GH-deficient adults improves exercise
performance and strength. There is also evidence that sup-
raphysiological GH exerts a protein anabolic effect in ath-
letes, both at rest and during exercise, although it is not
known whether this effect translates into improved perfor-
mance. Despite this lack of evidence, there is an expectation
among athletes that by attaining supraphysiological levels of
GH, their physical performance may be enhanced.
Abuse of GH is undesirable because of unfair competition
and also, as illustrated by the pathophysiological model of
acromegaly, because the maintenance of supraphysiological
levels of GH is detrimental to health (7). Although it is clearly
essential to develop a detection strategy for GH abuse, sev-
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eral factors complicate this task. Exogenous recombinant
human GH (r-hGH) and endogenous GH have identical
amino acid sequences, making chemical distinction impos-
sible. GH is secreted in a pulsatile manner and is under the
influence of stress, exercise, sleep, and food intake (8). This
pattern of secretion results in serum concentrations that vary
widely throughout the day and frequently overlapwithmea-
surements obtained after exogenous administration of GH.
Measurement of urinary GH has been previously demon-
strated to be insensitive as a marker of either GH adminis-
tration or acromegaly (9, 10).
To overcome the problems that surround the direct mea-
surement of GH, we have recently identified a series of
markers of GH action, which includes components of the
IGF/IGF-binding protein (IGFBP) axis and markers of bone
and collagen turnover and which shows promise as the basis
for a test for GH abuse (11, 12). These markers have been
identified, by assessing the effects of acute exercise, GH
administration, and GH withdrawal on a large number of
physiological substances that are influenced by GH. The
markers that we have selected are responsive to GH admin-
istration, but less sensitive to the acute effects of exercise
(11–15). We have demonstrated that GH administration in-
duces predictable modifications in these markers that persist
after GHwithdrawal and allow for clear discrimination to be
made between placebo- and GH-treated groups (13, 15).
Before thesemarkers ofGHadministrationmaybe applied
as a basis for a doping detection strategy, it is necessary to
construct appropriate normative data against which an in-
dividual result may be compared. Where reference ranges
exist for these markers, they have been constructed from
nonathletic populations. Values in athletes may differ sig-
nificantly from those in a nonathletic population, reflecting
the effects of physical training, acute exercise, genetic back-
ground, and the athletic physique. In this study we have
measured markers of the IGF/IGFBP axis and markers of
bone and soft tissue turnover in serum samples collected
from 813 elite athletes after a major competitive event, the
situation in which a doping test is most likely to be applied.
We have compared these results with values obtained from
elite athletes under resting conditions and with previously
published normative data (16). Finally, we have studied vari-
ables that might influence these normative data, such as age,
gender, body habitus, sporting discipline, and racial origin,
and used this information to construct reference ranges,
which may be applied under resting conditions and in the
postcompetition setting, to detect doping with GH.
Subjects and Methods
Subjects and sample collection
Samples were collected from 813 volunteer elite athletes (athletes
competing at the national or international level) within 2 h of a major
competitive event at the regional, national, or international level. De-
mographic data are given in Tables 1 and 2.
The nature of the project was explained to the athletes before their
participation in their event, and written informed consent was obtained
immediately before blood sampling. All samples were taken by a mem-
ber of the GH-2000 team and collected according to a standardized
protocol at the sporting venue where the event had taken place. Before
sample collection, the following demographic data were recorded: gen-
der, race, height (self-reported), weight (measured using the Tanita
TB7–305 bioimpedance analyzer, Tanita, Tokyo, Japan), age, and sport-
ing category. During sampling, volunteers were seated, and blood was
drawn from a vein in the antecubital fossa using a Vacutainer (BD
Biosciences, Franklin Lakes, NJ) and 20-gauge needle into two 5-ml
bottles containing SST clot activator gel. Samples were left to clot for 15
min at room temperature before being centrifuged at 1500 rpm in a
portable centrifuge. Two-milliliter aliquots of serum were then trans-
ferred by pipette into small storage tubes (Cryotubes) and immediately
placed on dry ice. They were subsequently transferred on dry ice to
storage at 80 C in the four participating GH-2000 centers.
Results were compared with both previously published normative
data (IGF-I only) derived from 400 healthy Swedish volunteers and
resting samples (all variables) from 262 elite athletes, which were also
collected as part of the GH-2000 project. All samples were measured in
the same laboratory.
The West Lambeth Health Authority gave ethics approval for this
study.
Analytical methods
All samples were coded and kept at 80 C until analyzed at one of
two central reference laboratories: Sahlgrenska Hospital (Gothenburg,
Sweden) and Kolling Institute (Sydney, Australia). Serum IGF-I, pro-
collagen type III (PIIIP), carboxyl-terminal cross-linked telopeptide of
type I collagen (ICTP), and carboxyl-terminal propeptide of type I pro-
collagen (PICP) were determined in Gothenburg, Sweden, and IGFBP-2,
IGFBP-3, and acid-labile subunit (ALS) were measured in Sydney,
Australia.
SerumGHwas determined by immunoradiometric assay (Pharmacia
TABLE 2. Characteristics of elite female athletes according to the








Power lifting 1 41 156 51 20.4
Basketball 14 21  3 176  6 68  5 22.0  1.4
Swimming 90 21  4 173  6 64  7 21.5  1.6
Marathon 8 36  7 165  6 54  4 19.7  2.4
Canoeing 4 34  8 164  8 58  10 21.5  1.3
Rowing 33 26  4 174  8 68  10 22.4  1.8
Cross-country
skiing
14 23  2 168  4 59  6 21.0  1.7
Alpine skiing 19 24  3 168  6 62  5 21.7  2.2
Weightlifting 7 25  5 162  7 63  14 23.9  5.1
Olympic handball 35 24  4 172  5 67  6 22.5  1.6
Track and field 51 26  5 171  7 63  12 21.2  3.1
Values are the mean  SD.
TABLE 1. Characteristics of elite male athletes according to the








Power lifting 20 35  5 170  10 85  19 29.8  1.6
Basketball 27 25  5 192  8 91  13 24.4  0.4
Football 46 24  4 178  7 74  8 23.3  0.3
Swimming 100 22  3 187  39 81  9 23.2  0.3
Marathon 8 36  12 173  7 66  6 22.0  0.7
Canoeing 10 26  6 183  5 81  5 24.1  0.6
Rowing 73 27  4 187  8 82  11 23.5  0.2
Cross-country
skiing
20 23  2 181  4 74  6 22.6  0.3
Alpine skiing 17 24  3 183  5 82  6 24.4  0.3
Weightlifting 10 29  6 177  6 79  13 25.2  1.2
Judo 26 27  7 177  7 74  7 23.18  0.4
Bandy 21 27  4 180  7 80  7 24.7  0.3
Ice hockey 38 26  4 181  5 85  5 25.9  0.2
Olympic handball 23 27  3 189  6 90  12 25.1  0.5
Track and field 98 26  5 182  8 78  17 23.4  0.4
Values are the mean  SD.
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Biotech, Uppsala, Sweden), with within-assay coefficients of variation
(CVs) of 10%, less than 5%, and less than 5%, and between-assay CVs
of 9.0%, less than 5%, and 7% at 10, 23, and 43 mU/liter, respectively.
Serum IGF-I wasmeasured by RIA using amonoclonal antibody after
acid-ethanol extraction (17), with within-assay CVs of 6.6%, 4.4%, and
2.3%, and between-assay CVs of 9.7%, 7.0%, and 4.6% at 104, 281, and
1324 ng/ml. Results were compared with previously published popu-
lation-based reference data from the same laboratory (16). The analyses
used on both occasions were carried out using the same technique and
the same antisera.
IGFBP-2 (18), IGFBP-3 (19), andALS (20)were assayed using in-house
RIAs and polyclonal antibodies. Serum IGFBP-2 within-assay CVs were
2.8%, 2.8%, and 3.2% at 140, 275, and 595 g/liter, and between-assay
CVs were 14.1%, and 12.7% at 65 and 775 g/liter, respectively.
Serum IGFBP-3 within-assay CVs were 6.2%, 5.5%, and 4.5% at 2.5,
5.7, and 12.6 mg/liter, and between-assay CVs were 11.9%, 14.5%, and
13.1% at 2.5, 5.7, and 12.6 mg/liter, respectively.
Serum ALS within-assay CVs were 3.4%, 3.3%, and 3.4% at 60, 245,
and 502 nmol/liter, and between-assay CVs were 10.5%, 5.4%, and 6.5%
at 62, 282, and 676 nmol/liter, respectively.
Serum osteocalcin was measured by RIA (OSTK-PR In Vitro Test Kit,
CIS Biointernational, Oris Industries, Gif-sur-Yvette, France); thewithin-
assay CVswere 3.7% and 3.0% at 3.8 and 24.7 g/liter, and the between-
assay CVs were 6.6% and 5.5% at 3.8 and 24.7 g/liter.
Serum PICP was measured by RIA (Orion Diagnostica, Espoo, Fin-
land); the within-assay CVs were 2.1% and 3.2% at 103 and 415 g/liter,
and the between-assay CVs were 4.1% and 4.0% at 105 and 435 g/liter.
Serum ICTPwas measured by RIA (Orion Diagnostica); within-assay
CVs were 6.2% and 4.4% at 3.8 and 11.2 g/liter, and the between-assay
CVs were 7.9% and 6.5% at 3.3 and 10.5 g/liter.
Serum PIIIP was measured by a two-stage sandwich RIA (CIS Bioin-
ternational; as described above); total assay CVs (within- plus between-
assay) were 9.1%, 5.7%, and 6.8% at 0.62, 0.95, and 1.18 g/liter.
Data analysis
Data analysis revealed that age was the single most important de-
terminant of all eight variables. Therefore, we initially determined the
form of the relationship between age and each of the markers and found
that a linear relation between the logarithm of the markers and the
reciprocal of age represented the best-fit relationship. Because our anal-
ysis disproved the hypothesis that both sexes have a common relation-
ship between marker and age, the two sexes were treated separately.
Any independent influence of height, weight, and body mass index
(BMI) was determined using stepwise multiple regression analysis after
adjustment for the effects of age. The influence of sporting category on
each of the variables was assessed before and after adjustment for age,
using ANOVA. Resting and postcompetition samples were compared
using unpaired t tests; although a few subjects provided resting and
postcompetition samples, most subjects provided only one sample for
this exercise, justifying the use of unpaired tests.
Using the model, y  x random error, where y represents the
logarithm of a marker, and x represents the reciprocal of age; prediction
intervals (reference ranges) were constructed for each marker. Regres-
sion analyses for each combination of marker and gender provided least
squares estimates (a and b) of the intercept  and slope  of the rela-
tionship between y and x together with an estimate of the residual sd.
Approximate lower (L) and upper (U) prediction limits for an obser-
vation on y at a given value of x are thus provided as: L  a  bx  ts
and U  a  bx  ts, where t is the appropriate percentage point of the
t distribution. The value t is dependent upon sample size, and in our
large dataset it is appropriate to replace t values with the equivalent
normal values, 1.960 for a 95% range and 2.576 for a 99% range. Because
the prediction intervals are expressed on a logarithmic scale, the limits
for a marker in natural units are eL and eU.
To investigate any possible racial influence on analytes, each black
athlete was pair-matched with the white athlete who was most similar
with regard to age, gender, height, and weight, and sporting category.
Black and white athletes were then compared using paired t tests. This
method of analysis was performed in view of the small number of black
athletes studied. All statistical comparisons were two-tailed. P  0.05
was considered statistically significant.
Results
Postcompetition samples were collected from 813 athletes
from 15 different sporting categories. Five hundred and thir-
ty-seven of the samples collected were drawn from male
athletes, and 276 were from female athletes. Male athletes
were older (26.5  5.3 vs. 25.1  5.4 yr; P  0.02), taller
(182.3  8.5 vs. 171.1  7.2 cm; P  0.001), and had a greater
BMI (24.1  3 vs. 21.8  2.5 kg/m2; P  0.001) than female
athletes. Age, height, and BMI varied widely between the
sports, reflecting the different nature of each discipline
(Tables 1 and 2). Resting samples were collected from 262
athletes. The distribution of age (26.5 5.3 yr), gender, and
BMI (23.2  2.5 kg/m2) in these subjects did not differ
significantly from that in the postcompetition group.
IGF-I/IGFBP axis
Forty-one percent of IGF-I values in males and 41% of
values in females were above the upper limits of 99% ref-
erence ranges derived from normal subjects 25 yr and older
under resting conditions (Fig. 1). When only subjects greater
than 25 yr of age were considered, 24% of IGF-I values in
males and 21% of values in females were above the upper
limits of this range. The dependence of all components of the
IGF-I/IGFBP axis on age was best represented through a
model inwhich the logarithm of themarker depends linearly
on the reciprocal of age. IGF-I, IGFBP-3, andALS all declined
with age, whereas IGFBP-2 increased with age (Fig. 2). The
percent decline in IGF-I (35%/decade) was more marked
FIG. 1. Comparison of IGF-I levels (nanograms per milliliter) mea-
sured in the postcompetition setting in 537 elite male athletes (A) and
276 elite female athletes (B) with laboratory reference data obtained
from a normal Swedish population.
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than the percent decline in IGFBP-3 (9%/decade) and ALS
(11%/decade).
Over the main age range for the data available here,
IGF-I, IGFBP-3, and ALS were greater, on the average, in
women, whereas IGFBP-2 was greater, on the average, in
men. There was no significant influence of height on any
of these variables in either males or females, whereas BMI
exerted a small, but significant, independent positive ef-
fect on IGFBP-2 in both males (r2  0.109) and females
(r2  0.030). BMI had no significant effect on any other
marker.
Markers of bone and collagen turnover
The relationship between age and each of the bone mark-
ers was also best fitted using a linear model between the
logarithm of the marker and the reciprocal of age. There was
a decline in all markers of bone turnover with age (Fig. 3).
Osteocalcin declined by an average of 15%/decade, PICP by
5%/decade, ICTPby 38%/decade, andPIIIP by 19%/decade.
Over the main age range for the data available here, os-
teocalcin, PICP, ICTP, and PIIIPwere greater, on the average,
in men. BMI exerted a small, but significant, independent
positive influence on PICP in male athletes only (r2  0.01).
Height had no significant effect.
Comparison of resting and postcompetition values and
influence of sporting category
In male athletes, IGF-I, IGFBP-2, IGFBP-3, ALS, ICTP, and
PIIIP were all higher, whereas osteocalcin was lower, in the
postcompetition setting than under resting conditions (Table
3). In female athletes, IGFBP-2, IGFBP-3, ALS, and PIIIPwere
all higher, and osteocalcin was lower, in the postcompetition
setting than under resting conditions (Table 3). There was a
strong trend (P  0.054) for IGF-I to be higher in female
athletes postcompetition compared with resting conditions.
The influence of sporting category on each of the variables
was assessed before and after adjustment for age. Initial
analysis suggested wide variation in all variables between
sporting categories, but after correction for age, there were
nomajor differences in any of the variables between sporting
categories. It can be seen in Fig. 4 that after age adjustment,
intersport variability was much reduced. Differences be-
tween sports were not significant once the age-adjustment
had been performed.
Influence of race
Mean levels of IGFBP-2 and IGFBP-3 were significantly
lower in black athletes compared with pair-matched white
athletes. There were no significant differences in any other
FIG. 2. Age-dependent change in components of the IGF/IGFBP system in 537 elite male (X) and 276 elite female (O) athletes. Reference ranges
for male (solid lines) and female (dashed lines) athletes are shown.
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variables (Table 4). Analysis was repeated after removal of
the two female subjects in each group, with no significant
effect on the findings.
Reference ranges
Because age and gender proved to be the principal deter-
minants of each of the markers, age-related reference ranges
were constructed for male and female athletes individually
(Figs. 2 and 3).
Table 5 displays the values a, b, and sderived from the least
squares analysis for each of the eight markers. The 99%
reference range at any given age will be given by eL and eU,
where L  a  b/age  2.576, U  a  b/age  2.576. a and
b are the least squares estimates of the relationship between
y, the log (marker), and x, the reciprocal of age, and s is the
residual sd. This approximation is valid because the number
of data points is large, and as long as no extrapolation is
attempted, the limits given will be good approximations for
ages in the range from about 16–45 yr. The following ex-
amples illustrate the use of these values to generate 99%
prediction intervals for ICTP.
Male, age 16 yr. On a log scale, 0.339  29.5/16  2.576 
0.2614 gives the approximate limits. Hence, L 1.51 andU
2.86, and the 99% reference range is (eL, eU), or (4.52, 17.39
g/liter).
Female, age 16 yr. The corresponding limits are 0.566  19.8/
16  2.576  0.2615 on the log scale, giving (3.10, 11.91
g/liter) for ICTP in its natural scale.
Discussion
This cross-sectional study demonstrates that age is the
most important determinant of postexercise serum levels of
components of the IGF-I/IGFBP system andmarkers of bone
and collagen turnover in elite athletes. As shown clearly in
Figs. 2 and 3, gender has a much smaller effect than age and
produces a reference range that is age-related, but, encom-
passing both genders, differs very little from the gender-
specific reference range. Once adjustment has been made for
age and gender, then demographic characteristics and the
nature of the exercise performed exert little or no influence
on any of these variables. These results have allowed devel-
opment of age- andgender-specific normative data, and from
this the construction of appropriate reference ranges, which
can be applied in the development of a test for GH abuse by
athletes.
All components of the IGF-I ternary complex (IGF-I,
FIG. 3. Age-dependent change in markers of bone turnover in 537 elite male (X) and 276 elite female (O) athletes. Reference ranges for male
(solid lines) and female (dashed lines) athletes are shown.
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IGFBP-3, and ALS) declined with age, whereas IGFBP-2
increased with age. GH exerts powerful stimulatory reg-
ulation over IGF-I, and age-related changes in IGF-I
closely correspond to age-related changes in integrated
24-h GH secretion. Interpretation of age-related changes in
GH-IGF-I activity, however, is complicated by concurrent
age-related changes in body composition and physical
fitness, variables that also influence GH secretion. It has
been hypothesized that the age-related fall in GH-IGF-I
activity may occur secondary to age-related changes in
body composition or physical fitness (21), rather than be-
ing an inherent part of the ageing process (6). A recent
study, however, that compared older and younger subjects
matched for lean body mass and fat mass provided evi-
dence that the age-related decline in GH secretion is in-
dependent of changes in body composition (22). Consis-
tent with this finding, the age-related decline in IGF-I
observed in elite athletes in the current study is at least as
marked as previous reports of the age-related decline in
sedentary subjects (16, 23, 24).
Postexercise levels of all components of the IGF/IGFBP
axis were greater than resting values. This finding is con-
sistent with our previous report that acute exhaustive exer-
cise induces an increase in all of these variables that is max-
imal by the end of exercise and has returned to baseline
within 2 h of completion of exercise (14). Approximately 40%
of IGF-I levels were above a 99% reference range previously
derived in normal subjects 25 yr of age and older, in which
a linear relationship between age and IGF-I was assumed
(16). Detailed analysis of the data in the current study con-
firmed the nonlinearity of that relationship, as previously
demonstrated by Juul et al. (25). Notably, many of elevated
IGF-I levels were derived from younger subjects, consistent
with the very high levels of IGF-I that occur during and after
puberty. It is likely that the discrepancy between the post-
competition values recorded in this study and the reference
range derived by Landin-Wilhelmsen (16) reflects a combi-
nation of the acute effects of exercise, clearly demonstrating
the need for reference data specifically applicable to athletes,
the inappropriate assumption of a linear relationship be-
tween age and IGF-I in that report, and possibly recent pu-
FIG. 4. A, Logarithmically transformed IGF-I levels in elite male
athletes from 15 different sports. B, Box plots of age-adjusted resid-
uals obtained by regressing these logarithmically transformed IGF-I
levels on the reciprocal of age.
TABLE 3. Comparison of results of GH-dependent variables in resting and postcompetition samples from elite athletes
Male Female
Resting (n  267) Post competition (n  813) Resting (n  267) Post competition (n  813)
IGF-I (ng/ml) 308 (93) 333 (108)a 352 (104) 381 (123)
IGFBP-2 (g/liter) 216 (82) 239 (103)a 180 (91) 207 (109)a
IGFBP-3 (mg/liter) 4.2 (0.8) 4.7 (1.0)a 4.7 (0.8) 5.1 (1.1)a
ALS (nmol/liter) 241 (50) 277 (68)a 298 (85) 340 (95)a
Osteocalcin (g/liter) 12.7 (3.3) 10.9 (3.4)a 10.2 (3.4) 8.8 (3.9)a
PICP (g/liter) 202 (74) 190 (73) 182 (57) 175 (68)
ICTP (g/liter) 4.6 (1.5) 4.9 (2.0)a 4.3 (1.2) 4.4 (1.5)
PIIIP (g/liter) 0.64 (0.18) 0.57 (0.13)a 0.62 (0.19) 0.56 (0.15)a
All values are means (SD).
a P  0.01 vs. resting values.
TABLE 4. Comparison of results of GH-dependent variables in
samples from 35 black athletes and 35 white athletes, pair-
matched for demographic characteristics
White Black
Male/female 33/2 33/2
Age (yr) 25.8 (0.8) 25.6 (1.0)
Weight (kg) 78.0 (2.3) 75.6 (2.4)
Height (cm) 182.3 (1.3) 179.9 (1.5)
IGF-I (ng/ml) 317 (19) 321 (16)
IGFBP-2 (g/liter) 296 (25)a 222 (16)
IGFBP-3 (mg/liter) 4.83 (0.21)a 4.32 (0.15)
ALS (nmol/liter) 254 (12) 236 (7)
Osteocalcin (g/liter) 10.7 (0.5) 11.0 (0.6)
PICP (g/liter) 182 (17) 151 (5)
ICTP (g/liter) 5.17 (0.29) 5.47 (0.38)
PIIIP (g/liter) 0.69 (0.03) 0.71 (0.04)
All values are means (SEM).
a P  0.05 vs. black athletes.
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berty in some of the younger subjects. Additional data are
needed before the results in this study can be safely used in
athletes who are peripubertal or recently postpubertal.
IGF-I, IGFBP-3, and ALS were higher, on the average, in
females,whereas IGFBP-2was higher inmales. The influence
of gender on GH-IGF-I activity is extremely complex. There
is a sexually dimorphic pattern of GH secretion (26). Paren-
teral testosterone increases IGF-I in normal men (27). Orally
administered estrogen reduces the IGF-I response to GH, but
also leads to increased GH secretion, probably at least partly
secondary to reduced negative feedback by circulating IGF-I
(28). Orally administered estrogen also reduces levels of
IGFBP-3 and ALS (29). An exploration of the moderating
effect of oral contraceptive usage on the data collected from
the female athletes was beyond the scope of this study and
requires additional investigation.
After adjustment for age and gender, the relationship be-
tween BMI and IGF-I/IGFBP activity was weak, although
there was a positive correlation with IGFBP-2. In normal
population groups, GH secretion is influenced by body fat
distribution. Increased visceral fat is associated with lower
serum IGF-I concentrations (30, 31) and decreased sponta-
neous (28) and exercise-induced (32) GH release. However,
the relationship between axiological characteristics and com-
ponents of the IGF-I/IGFBP axis may differ in athletic pop-
ulations, because, firstly, body fat is much lower than in a
normal nonathletic cohort, and secondly, athletes are likely
to have an increased lean body to fat mass ratio, even when
compared with normal subjects with a similar BMI.
IGFBP-2 and IGFBP-3 were lower in black athletes com-
pared with a closely matched population of white athletes.
Reduced IGFBP-3 despite increased integrated 24-h GH se-
cretion has previously been documented in normal black
men (33). To our knowledge, reduced IGFBP-2 in a black
population has not been previously described. The physio-
logical consequences of these changes are not known, but
may be important. However, in the context of development
of a test for doping with GH, these findings may be of major
importance and warrant additional investigation of the GH-
IGF-I axis in different racial groups. It should be emphasized
that these are preliminary data and require validation in a
much larger population.
The markers of bone formation reported in this study
reflect different stages of osteoblastic cell function (34). Os-
teocalcin is generated during bone mineralization. Earlier
phases of the bone-remodeling process involve the deposi-
tion of collagen scaffolding, which generates PICP. ICTP is
amarker of bone resorption. In contrast to these bone-specific
markers, PIIIP does not appear to be present in bone (except
during callus formation after fracture), reflecting extraosse-
ous collagen formation, particularly in normal ligament and
tendinous structures and in pathological states of collagen
deposition, such as hepatic fibrosis (35, 36). All of themarkers
of bone turnover declined with age. Although a large body
of literature exists concerning the effect of age on bone turn-
over in postmenopausal and elderly subjects, little work has
been carried out in younger subjects. In one of the few studies
that included subjects of a similar age to those in the current
study, Fatayerdi and Eastell (6) demonstrated that the influ-
ence of age on PICP, osteocalcin, and ICTP was best de-
scribed by quadratic functions, with a decline in younger
subjects, a nadir in the sixth decade, and an increase there-
after. This is compatible with our findings. Although we
found no advantage in using a quadratic compared with a
log-linear function, this is probably explained by the fact that
we did not study subjects beyond the fifth decade and thus
did not observe a leveling out of these markers.
The observation that postcompetition levels of some of the
variables differed from resting data are compatible with our
previous observations that exercise exerts a small, but sig-
nificant, effect on both the IGF/IGFBP system and markers
of bone and soft tissue turnover (11, 12). However, after
adjustment for age, despite major differences in the nature
and duration of the exercise performed, there were no sub-
stantial differences between sports for either components of
the IGF/IGFBP system or markers of bone and soft tissue
turnover. This finding is clearly of importance when devel-
oping a test for GH doping, because it implies that expected
values will not differ depending on the nature of the sport
performed. In addition to the acute effects of exercise, it is
possible that postcompetition levels of some analytes are
influenced by precompetition training practices. Generally,
athletes will taper for a period of time (depending on the
sport) before an event, which consists of doing a smaller
volume of training but still training at a high intensity. How
this affects components of the IGF/IGFBP system is not
known.
The reference ranges quoted are specific to the assays and
reagents used in this project. It is the nature of immunoassays
thatmeasurements are not absolute and inevitably a function
of the reagents and conditions used in the assay. If immu-
noassays are to be used in a test for GH abuse that may lead
to sanctions on an elite athlete, it will be necessary for the
laboratory concerned to be able to demonstrate validation of
their assays with the results reported here. Furthermore, in
the development of a widely available test for GH abuse, it
will be essential to develop assays using specific reagents
that can be accredited to an international standard and reg-
ularly monitored by the International Olympic Committee
TABLE 5. Values of intercept, slope, and SD for prediction
intervals for markers for male and female athletes treated
separately
Marker Sex A B S
IGF-I (ng/ml) M 4.80 23.7 0.2681
F 4.97 20.9 0.2623
IGFBP-2 (g/liter) M 5.99 15.6 0.4097
F 5.99 20.2 0.4691
IGFBP-3 (mg/liter) M 1.18 8.37 0.2099
F 1.49 2.58 0.2172
ALS (nmol/liter) M 5.29 7.68 0.2280
F 5.56 5.33 0.2781
Osteocalcin (g/liter) M 1.81 12.9 0.3326
F 1.44 14.2 0.5140
PICP (g/liter) M 5.04 3.78 0.3303
F 4.67 9.62 0.3427
ICTP (g/liter) M 0.339 29.5 0.2614
F 0.566 5.33 0.2781
PIIIP (g/liter) M 1.13 15.9 0.2357
F 1.03 11.6 0.2854
Thenumbers in the table are not directly in the units given (see text
for further details).
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and the World Anti Doping Agency. The introduction of
specific mass spectrometric assays for these protein hor-
mones now seems feasible, and these may, in turn, replace
immunoassays (at least for confirmation of the results of a
screening test) and facilitate international standardization.
The results presented here can only be used in the context of
white elite athletes. Additional research is needed on the
sensitivity of other ethnic groups to exogenous r-hGH.
The markers described in this study represent one of the
most promising approaches to detection of GH abuse by
athletes. An alternative approach makes use of the observa-
tion that although GH circulates predominantly as a 22-kDa
isoform, there are also measurable amounts of other iso-
forms, including 17- and 20-kDa isoforms present in human
serum. In contrast, r-hGH is entirely composed of the 22-kDa
isoform, and therefore, it is possible that the ratio of other
isoforms to 22-kDa GH in serum may differentiate endoge-
nous and exogenous GH.
In summary, we have demonstrated that age is the most
important predictor of serum levels of markers of GH drawn
both from markers of GH action and from markers of bone
and collagen turnover, reflecting the fall in GH secretion that
normally occurs with ageing (somatopause). Results differ
significantly betweenmale and female athletes, although the
impact of gender is less important than that of age. Using this
information, we have constructed age-related reference
ranges appropriate to elite white male and female athletes
that are suitable for use under resting conditions and in the
postcompetition setting. Because neither sporting category
nor demographic characteristics were important predictors
of levels of the selected markers, this range is applicable to
athletes of all sporting disciplines. Establishment of appro-
priate reference data against which the results of an indi-
vidual athlete may be compared is an important step in the
development of a doping detection strategy to combat GH
abuse. Assay validation will be a key step in the introduction
of a robust test to detect GH abuse.
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